These findings, if validated in larger sets of prospective clinical studies, might be useful for the management of glioma patients, because, in the context of a disease, whose prognosis is usually dismal, the NSUN5 epigenetic lesion contributes to identify those patients who are likely to have a good outcome. Here, NSUN5 is linked to central nervous system cancer.